Novartis Ag (NVS) Amortization - Intangibles (2009 - 2010)
Novartis Ag recorded quarterly Amortization - Intangibles of $274.0 in Q2 2010, down 1.79% quarter-over-quarter from $279.0 in Q1 2010, and up 7.03% year-over-year from $256.0 in Q2 2009.
Novartis Ag's Amortization - Intangibles history runs 2 years deep, the most recent figure standing at $274.0 for Q2 2010.
- In Q2 2010, Amortization - Intangibles rose 7.03% year-over-year to $274.0; the TTM figure through Jun 2010 stood at $274.0 (up 7.03% YoY), while the FY2009 annual figure was $265.0, changed N/A from the prior year.
- Amortization - Intangibles came in at $274.0 for Q2 2010 at Novartis Ag, down from $279.0 in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $279.0 in Q1 2010 to a low of $248.0 in Q1 2009.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2010 | 274.00 |
| Mar 31, 2010 | 279.00 |
| Dec 31, 2009 | 265.00 |
| Jun 30, 2009 | 256.00 |
| Mar 31, 2009 | 248.00 |